Tian'an Pharmaceutical Co Ltd

Tian'an Pharmaceutical maintains a strong liquidity position, with a current ratio of 14.21, indicating a significant excess of current assets over current liabilities. The company holds $8.226 million in cash and equivalents, and its total liabilities are relatively low at $0.953 million, with no long-term debt outstanding. This liquidity profile supports operational flexibility and reduces financial risk. The company's profitability is robust, with a net income of $3.142 million and a return on equity of 21.77%, which is well above the typical benchmark for pharmaceutical firms. Gross profit of $7.299 million and operating income of $3.698 million further underscore its strong cost control and pricing power. These metrics suggest a healthy margin structure and efficient operations. Tian'an Pharmaceutical's revenue is concentrated in the domestic market, as disclosed in its business description, with no material international revenue segments reported. The company's product portfolio includes Compound Ginseng capsule, Nizhuanle Yin granule, and Tianan Pain Relief Capsule, which are central to its revenue generation. No material segment-specific financial data is available, but the disclosed product lines suggest a diversified yet focused approach to traditional Chinese medicine. The company's growth trajectory is not explicitly detailed in the latest financials, but its strong profitability and liquidity suggest a stable and potentially growing business. No specific revenue growth rates or future projections are provided in the available data. However, the absence of long-term debt and the presence of significant cash reserves indicate a conservative capital structure that supports long-term stability. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of dilution pressures, as shares outstanding remain unchanged between basic and diluted measures. No recent events, such as filings or transcripts, are reported in the available data to suggest material changes in risk exposure. No recent events, such as filings or transcripts, are reported in the available data to suggest material changes in the company's operations or risk profile. The company's financial and operational disclosures remain consistent with a stable and conservative business model.